Mangoceuticals Inc (MGRX)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-11-05
$0.19-7.39%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-11-05
QuarterlyIQ Insights · MGRX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 56.5% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of —
MGRX — debt issuance
Dated 2026-10-09
Entry into a Material Definitive Agreement. On October 8, 2026, Mangoceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors, in a registered direct offering (the “Offering”), (i) 657,000 shares (the “Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company, (ii) common warrants to purchase up to 657…
Why it matters: Nasdaq requires a closing bid of at least $1.00 for 10 straight business days. Missing the deadline puts the listing at risk.
Worry ifMGRX closes at or above $1.00 for at least 10 straight business days by Feb. 1, 2027.
Less concerning ifMGRX fails to meet that test by Feb. 1, or Nasdaq begins delisting action.
Why it matters: Losses improved through 2026-Q2, but the company remains loss-making. A smaller loss would extend that progress; a larger one would reverse it.
Watch forThe Nov. 13 report shows operating loss below $1.03 million and net loss below $1.31 million.
Also watch forThe report shows operating loss above $1.03 million or net loss above $1.31 million.
Why it matters: A signed deal would show that the antiviral patent portfolio has a path to market. No deal would leave commercialization unproven.
Supportive ifA company filing or release names a deal to license, sell, or distribute MGX-0024.
Worry ifA filing or release says no deal was reached, or reports that commercialization plans have stopped.
Why it matters: The payment would complete the $2.5 million commitment for antiviral work. A missed payment would leave the funding plan short.
Watch forMangoRx IP confirms it received the remaining $750,000 by Nov. 28, 2026.
Also watch forThe $750,000 remains unpaid after Nov. 28, or the subscription agreement is ended.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$451 on $10,000 · ±4.5% | How much price usually moves either way. |
| Bad day | $1,591 loss on $10,000 · 15.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,267 loss on $10,000 · 92.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.